Vancouver, British Columbia, April 22, 2026 - TheNewswire – Noveris Health Sciences Inc. (the “Company”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce that it has entered into an advisory agreement (the “Agreement”) with DS Market Solutions Inc. (“DSMS”), pursuant to which DSMS will provide liquidity and stability services to the Company in accordance with the policies of the Canadian Securities Exchange.

Pursuant to the Agreement, DSMS will assist in entering orders, including bidding and offering, and will provide the Company with information regarding trading patterns in its securities on the CSE, as well as reports on services performed by DSMS. DSMS will receive compensation of $10,000 per month (plus applicable taxes). The engagement will become effective on May 1, 2026 and will continue on a month-to-month basis unless terminated by either party upon 30 days' written notice.

There are no performance factors contained in the Agreement. DSMS will not receive shares or options as compensation and will not provide promotional or investor relations services on behalf of the Company. DSMS is arm's length to the Company and, to the knowledge of the Company, neither DSMS nor its principals have any direct or indirect interest in the securities of the Company.

DS MARKET SOLUTIONS INC.

DSMS is an independent provider of equity trading advisory and liquidity services, with its principal place of business located at 1160 Walden Circle, Unit 6, Mississauga, Ontario.

Contact:

David Sears

Tel: 647-981-9474

Email: davidsears@dsmarketsolutions.com

Web: https://dsmarketingsolution.com/

NOVERIS HEALTH SCIENCES INC.

Jason Birmingham  

Chief Executive Officer  

Tel: +1 778-900-NVRS (6877)  

Investor Relations Email: fair@noveris.health  

Web: http://noveris.health

About Noveris Health Sciences Inc.  

The Company is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and posttraumatic stress disorder (PTSD).  

NEITHER THE CSE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.